ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00096603
Recruitment Status : Completed
First Posted : November 15, 2004
Last Update Posted : March 20, 2014
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Brief Summary:
This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Raptiva (efalizumab) Phase 3

Study Type : Interventional  (Clinical Trial)
Enrollment : 450 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter Study to Evaluate the Safety of 1.0 mg/kg Subcutaneously Administered Efalizumab in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g
Study Start Date : October 2002
Actual Study Completion Date : July 2004

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent
  • Previous participation in Study ACD2600g
  • For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

Exclusion Criteria:

  • Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab

Responsible Party: Genentech, Inc.
ClinicalTrials.gov Identifier: NCT00096603     History of Changes
Other Study ID Numbers: ACD2601g
First Posted: November 15, 2004    Key Record Dates
Last Update Posted: March 20, 2014
Last Verified: March 2014

Keywords provided by Genentech, Inc.:
Moderate to severe plaque psoriasis

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases